Intuitive Surgical sees FY26 income tax rate 22%-23%

Sees FY26 non-cash stock compensation expense $890M-$920M. Says expects primary growth drivers in FY26 of general surgery in the U.S. and procedures outside urology internationally. Says other factors impacting projected pro forma gross profit margin guidance include faster growth of newer products, da Vinci five and Ion modest incremental depreciation from recent facility expansion and the impact from higher da Vinci system upgrades, partially offset by cost reductions. Says expects that capital expenditures will return to more normalized levels. Says in Q4, received clearance for several additional indications, including nipple sparing mastectomy, inguinal hernia repair, cholecystectomy and appendectomy. Comments and guidance taken from Q4 earnings conference call.